Beruflich Dokumente
Kultur Dokumente
Immunosuppressed allograft recipients have three to five folds increase in cancer risk as compared to age
matched general population. The most common malignancies encountered are Non Melanotic Skin Cancer,
Post Transplant Lymphoproliferative Disorder and Kaposi’s Sarcoma. Duration of immunosuppressive
therapy and/or type of immunosuppressive agents are important controllable factors which have an impact in
the development of tumors. Oncogenic viruses have an important role in the development of these
malignancies.
Key words: Post transplant malignancy, Immunosuppressive agents.
INTRODUCTION INCIDENCE
Solid organs transplant is the only life saving modality Immunosuppressed allograft organ recipients have 3 to
for end stage disease of various organs. In past few decades 5 fold increase in cancer risk as compared to age matched
great advances have been made in the field of organ general population [4]. The most common malignancies
transplant. Availability of excellent infrastructure in leading encountered in post transplant recipients are non melanotic
hospitals, advancement of surgical techniques, growing skin cancers (NMSC - upto 82 %), PTLD (upto 11%) and
research and development of various safe options for Kaposi’s sarcoma (KS) (about 6%) [5-7]. Besides these
immunosuppression have lead to improvement in graft malignancies, other tumors showing higher frequency are
survival, increased life expectancy and morbidity free post renal cell carcinoma, in-situ carcinoma of uterine cervix,
transplant life in recipients. This has resulted in notable hepatobiliary carcinoma, anogential cancer and
increase in number of solid organ transplants. Currently gastrointestinal tumors [8]. US Renal Data System
survival rate of renal transplant recipients is 95% at 1 year (USRDS) database showed that incidence of common
and about 90% at 5 years [1]. cancers such as colon, lung, prostate and breast is two times
higher in post transplant recipients as compared to age
Recipients of solid organ transplant are exposed to matched population, while the increase in incidence ranges
prolonged immunosuppression which increases potential from 3 fold for bladder and testicular malignancies, 15 fold
risk of post transplant malignancies (PTM). In addition, for kidney malignancies and 20 fold for lymphomas and
relatively older individuals are being considered for NMSC [9].
transplants who carry inherent risk of malignancies. Thus
PTM is now a major challenge in patients successfully Netherland study showed that skin malignancy
treated by organ transplantation. Compared to general developed in 53% of patients after renal transplant and 48%
population, several types of malignancies occur more of this subsequently developed second malignancy. PTLD
commonly in transplant recipients and are often more developed in 11% of patients, of which 65% presented with
aggressive with far worse prognosis [2]. lymphoma. Skin malignancies usually have good
prognosis, PTLD has variable prognosis and GIT
In 1968, Starzl and Penn described the first case of Post malignancies have poor prognosis[6].
Transplant Lymphoproliferative Disorder (PTLD). Penn
established a voluntary Transplant Tumor Registry in 1969, Post transplant malignancies are a problem for
which was posthumously renamed as Israel Penn recipients of all types of organ transplants. The risk of
International Transplant Tumor registry (IPITTR) in honour PTLD being more after small bowel, heart and lung
of his life’s commitment to the study of transplant transplant than renal and liver transplants [10]. Reported
malignancies [3]. incidence of cancer in renal transplant recipients is 2.3-
31 % in published series [11]. Data from registry of stimulating angiogenesis mediated by Vascular Endothelial
International Heart and Lung Transplantation (ISHLT) Growth Factor (VEGF) has also been demonstrated [20]. In
shows that amongst the heart transplant recipients, 3.1% of vitro studies have suggested that cyclosporin induces
surviving patients develop some form of malignancy after 1 malignancy by reduction in p53 induced apoptosis and
year, which increased to 16.1% in 5 years survivors and suppression of UV induced DNA repair [16]. Purine
26.2% in 8 years survivors. Data from lung transplant analogues such as azathioprin, have also been used in post
recipients showed the same trend [12]. USRDS data transplant patients. Post transplant patients treated with
showed that in renal transplant recipients cumulative Purine analogues have a much more rapid development of
incidence of cancer excluding NMSC is 3.3% at 1 year and skin cancer in comparison those treated with cyclosporine
7.5% at 3 years [13]. [16,21].
transplant recipient is much lower i.e.1-3% as kidney after absence of response to reduction in
transplant recipients require relatively less severe immunosuppression treatment or simultaneously is still
immunosuppressive treatment [16]. debated [29].
Vast majority of PTLD are host derived. However some It is suggested that in monomorphic PTLD, starting
cases can be derived from donor lymphocytes transplanted rituximab at the same time as reducing immunosuppression
within the graft [28]. Sites of predilection for PTLD are is a justified approach, which increases the chances of
extranodal. Trasplanted organ and digestive tract are most complete remission [29]. In cases which are refractive to
frequent sites [29]. CNS is frequently involved in up to 30% first line treatment by rituximab, it is yet unclear whether
cases [30]. PTLD arising within one year of transplant is extended treatment by rituximab is appropriate or whether
usually associated with EBV infection and commonly polychemotherapy should be initiated. Because of higher
involves graft. This may suggest permissive role of graft rate of treatment related morbidity and mortality, use of
microenviorment in the pathogenesis [31]. rituximab has become more common [45]. Case series have
described response rate with single agent rituximab of
Most of the PTLD are B cell type, T cell lymphomas are around 60% [45]. Finally, adoptive T-cell immunotherapy,
only about 15% of these. T cell lymphomas tend to occur via infusion of EBV- specific CTLs in patients with EBV-
late and affect extranodal sites. HTLV-1 virus has been positive PTLD has shown promise [45].
implicated in pathogenesis of T cell lymphoma. [32].
PSIs have shown promising results in the treatment of
Duration, degree and type of immunosuppressive agent PTLD [46]. Data from centers in Europe of nineteen post
used greatly influence development of PTLD. Introduction renal transplant patients with PTLD have been pooled. In
of triple therapy i.e. cyclosporin, OKT3 antibody and these patients calcineurin inhibitor was withdrawn in
antithymocyte globulin is associated with increased risk eighteen and minimized in one with simultaneous
[33]. There is higher risk of PTLD with tacrolimus than conversion to PSIs. Concomitant CHOP was given in six
cyclosporin therapy in kidney transplant recipient [34]. and rituximab in another six. Fifteen out of eighteen patients
showed remission which was maintained for 6 to 56 months
Efforts have been made to identify patient at high risk of
[46]. Radiation therapy is method of treatment for CNS
developing PTLD by monitoring EBV-DNA load. No
lymphoproliferative disease [30].
threshhold values predictive of development of PTLD have
been identified [35]. However, a rising trend of EBV- DNA Kaposi’s Sarcoma (KS)
in a particular patient may define patient at risk [36]. Serial
raised IL-10 levels and a unique monoclonal serum protein The incidence of Kaposi’s Sarcoma (KS) in transplant
has been identified in patients who developed patients may be as high as 500 times than in healthy
PTLD [37,38]. Vaccine against EBV may provide individuals [7,47]. In renal transplants it is seen in upto 6%
protection to post transplant patients [39]. of recipients though recent data demonstrates a lower
overall incidence of 8.8 cases of KS per 1,00,000 person
Reduction in immunosuppression is first line of years [5]. Prevalence of KS in transplant recipients depends
treatment in the management of patients with PTLD. on geographical location, ranging from 0.5% in western
Complete regression of early lesions and polymorphic countries such as USA to 5.3% in Saudi Arabia. Majority of
PTLD usually occurs as a result. No standard guidelines cases occur in patient from Mediterranean, Jewish, Arabic,
exist, but decreasing cyclosporin/tacrolimus by 50% and Caribbean or African ethnic groups [7,47]. The median time
discontinuing azathioprin or mycophenolate is from transplantation to diagnosis of KS is about 1.5 years
recommended [40]. Immunosuppression should be reduced [48]. KS presents as cutaneous involvement in about 80%
to minimal possible safe level keeping in mind graft cases. Visceral involvement is seen in 20% cases. Lungs,
survival. Twenty five to 50% patients respond to reduction GIT and lymphoid tissue can be involved [47, 49]. The
in immunosuppression alone. Beneficial effect of antiviral pathogenesis of KS is related to the use of immuno-
agents such as cyclovir is doubtful [25]. suppressive drugs and subsequent viral infection [45].
HHV-8 is implicated in the pathogenesis of tumor
For last few years monoclonal antibody therapy development.
(rituximab) directed against B cell receptor (CD20) has
been introduced in treatment of B cell PTLD with promising The first association of KS and HHV-8 was made when
results [41-44]. Whether demonstration of CD20 virus was isolated from KS tissue in AIDS patients [50].
expression in biopsy is prerequisite for starting treatment is Various mechanisms may be involved in HHV-8 induced
not well established. When to start rituximab therapy is tumor development. HHV-8 proinflammatory proteins
another issue. Whether the treatment should be initiated might directly inhibit apoptosis and there by promote cell
transformation [51]. The virus might also modulate the addition to its role as mutagen, have immunosuppressive
major histocompatibity class 1 antigen presentation properties in the skin [7, 60]. Older age, male sex, presence
pathway making infected host cells invisible to cytotoxic T of permalignant lesions such as actinic keratosis and
lymphocyte surveillance [51]. Development of KS may cigarette smoking has also been associated with SCC and
involve initial latent HHV-8 infection of endothelial cells BCC [60].
and subsequent conversion in spindle cells. This is followed
by proliferative phase and expression of a lytic protein, viral Transplant recipients should be warned about sun
G protein coupled receptor (vGPCD). In endothelial cells exposure. Studies have demonstrated beneficial effect of
vGPCR oncoprotein increases secretion of VEGF and systemic retinoid chemoprophylaxis in transplant recipients
plays a pivotal role in development of tumor [52 ]. [45, 62]. However, a rebound effect with higher incidence of
NMSC after discontinuation of therapy is also reported.
Immunosuppresion is the key contributing factor for Standard therapy for NMSC includes Mohs’ micrographic
development of tumors. Use of cyclosporin as an surgery, superficial ablative therapy, cytotherapy and
immunosuppressive drug in post transplant patients is photodynamic therapy along with attenuation of
associated with a higher incidence of Kaposi’s sarcoma. immunosuppresion [63].
[47]. Reduction or discontinuation of immunosuppresssion
is the first line treatment for KS. Consensus guidelines for immunosuppression
reduction have been developed [64]. Extent of
Conversion of cyclosporin to low therapeutic doses of immunosuppression and type of immunosuppressive agents
mycophenolate mofetil can lead to regression of KS [53]. used may play a critical role. A recent study indicated that
PSIs (sirolimus and everolimus) through specific effect on incidence NMSC increased from 19% at less than 5 years to
VGEF may provide advantage of both immunosuppressive 47% after more than 20 years of immunosuppressive
and antineoplastic activity [54]. PSIs impair VEGF therapy [65]. A study in liver transplant receipient showed
production and limit response of endothelial cells to VEGF mycophenolate mofetil (MMF) was associated with
in animal models [54, 55]. Recurrence after reduction or increased risk of NMSC although this risk didn’t remain
change in immunosuppresion has been treated by after multivariate anlaysis [66], PSIS like sirolimus have
chemotherapy, Anthracycline based chemotherapy is the potential for reducing the incidence of NMSC [67].
usual line of treatment [45]. Paclitaxel has also shown Compared with 5% incidence of NMSC in cyclosporin
success in two phase II trials [56]. Imatinib (C-kit inhibitor) treated patients, no malignancies were observed in patients
and antiangiogenic agents like bevacizumab may also have receiving sirolimus as base therapy [68]. Thus cyclosporin
a role in treating KS [56-58]. free sirolimus based immunotherapy may reduce incidence
of post transplant skin malignancy.
NON MELANOTIC SKIN CANCER
CONCLUSION
Non melanotic skin cancer (NMSC) affects large
number of organ transplant patients. Basal cell carcinoma • Allograft organ recipients have three to five folds
(BCC) and squamous cell carcinoma (SCC) account for increase in cancer risk as compared to age matched
more than 90% of NMSC in transplant recipients [7]. general population.
Squamous cell carcinoma is the most common form of skin
• Post transplant immunosuppressive therapy resulting
cancer in these patients occurring at an incidence 65- 250
in impaired cancer surveillance and facilitating the
times greater than general population while incidence of
action of oncogenic substances including oncogenic
BCC is increased 10 fold after transplant [7]. This indicates
viruses are key factors in pathogenesis.
that normal ratio of 4:1 of BCC to SCC is reversed in
transplant recipients [7,59]. • The most common malignancies encountered in post
transplant recipients are NMSC (upto 82%), PTLD
Overall cumulative incidence of NMSC after (upto 11%) and KS (upto 6%).
transplantation ranges from 2-24% after 5 years and 7-33 %
after 10 years [60]. Lifelong immunosuppression is the most • PTLD has been classified by WHO as (i) early lesion
important factor in the pathogenesis of NMSC. In addition, characterized by infectious mononucleosis type
UV exposure, HPV infection, and genetic factors also play a picture or plasma cell proliferation, (ii) polymorphic
role. Mutations of p53 and proto-oncogenes may occur [7]. PTLD and; (iii) monomorphic PTLD. EBV has
important role in causing PTLD.
Fair skinned people living in countries with hot climate
and high ultra violet exposure are more at risk of developing • Prevention of post transplant malignancies by
post transplant NMSC [61]. Ultraviolet radiations, in judicious use of immunosuppressive agents and early
organ transplant recipients. Transplantation 1995; 59: 44. Gonzalez- Barca E, Domingo –Domenech E, Capote FJ,
240-244. et al. The GEL / TAMO, GELCAB, and GOTEL, Prospective
phase II trial of extended treatment with rituximab in
31. Bakker NA, Van Imhoff GW, Verschuuren EA, et al. Early
patients with B cell post lymphoproliferative disease.
onset post -transplant lymphoproliferative disease is
Haematologica 2007; 92: 1490-1495.
associated with allograft localization. Clin Transplant 2005;
19: 327-334. 45. Zafar SY, Howell DN, Gockerman JP. Malignancy after
solid organ transplantation: An overview. The Oncologist
32. Rajakarlar R, Bhattacharya N, Norton A, et al. Post
2008; 13 (7): 769-778.
transplant T- Cell lymphoma: A case series of four patients
from a single unit a review of literature. Am J Transplant 46. Pascual J. Post transplant lymphoproliferative disorder the
2004; 4: 1534-1538. potential of proliferation signel inhibitors Nephrol Dial
Transplant 2007; 22(supp 1): i 27-i 35.
33. Libertiny G, Watson CJ, Gray DW, et al. Rising incidence of
post transplant lymphoproliferative disease in kidney 47. Mendez JC, Paya CV. Kaposi’s sarcoma and
transplant recipients. Br J Surg 2001; 88: 1330-1334. transplantation. Herpes 2000; 7: 18-23.
34. Caillard S, Dharnidharka V, Agodoa L, et al. Post transplant 48. Mbulaiteye SM, Engels EA. Kaposi’s Sarcoma risk among
lymphoproliferative disorder after renal transplantation in transplant recipients in the United States (1993-2003). Int J
the United States in era of modern immunosuppression. Cancer 2006; 119: 2685-2691.
Transplantation 2005; 80: 1233-1234.
49. Tan HH, Gob CL. Viral infection effecting the skin in organ
35. Bakker NA. Von Imhoff GW, Verschuuren EA, et al. transplant recipients, epidemiology and current
Presentation and early detection of post transplant management strategies An, J Clin Dermatol 2006; 7: 13-
lymphoproliferative disorder after solid organ 29.
transplantation. Transplant Int 2007; 20: 207-218.
50. Chang Y, Cesarman E, Pessin MS, et al. identification of
36. Bakker NA, Verschuuren EA, Erasmua ME, et al. Epstein- herpes virus like DNA sequences in AIDS associated
Barr virus DNA load monitoring late after lung Kaposi’s Sarcoma. Science 1994; 266: 1865-1869.
transplantation : a surrogate marker of the degree of
51. Rezaee SA, Cunninghan C, Daison AJ, et al. Kaposi’s
immunosuppression and a safe guide to reduce
sarcoma associated herpes virus immune modulation ; An
immunosuppression. Transplantation 2007; 83: 433-438.
overview J, Gen Virol 2006; 87: 1781-1804.
37. Baiocchi OC, Colleoni GW, Caballero OL, et al. Epstein-
52. Campistol JM, Gutierrez Dalmau A, Torregrosa JV.
Barr viral load, interleukin-6 and interleukin-10 levels in
Conversion to sirolimus ; a successful treatment for post
post transplant lymphoproliferative disease : a nested
transplantation Kaposis Sarcoma. Transplantation 2004 ;
case-control study in a renal transplant cohort. Leuk
77: 760-762.
Lymphoma 2005; 46: 533-539.
53. Hussein MM, Mooij JM, Roujoulen HM. Regression of post
38. Tsai DE, Aqui NA, Tomaszewski JE, et al. Serum protein
transplant Kaposi’s sarcoma after discontinuing
electrophoresis abnormalities in adult solild organ
cyclosporin and giving mycophenolate mofetil instead,
transplant patents with post transplant lymphoproliferative
Nephrol Dial Transplant 2000; 15: 1103-1104.
disorders Clin Transplant 2005; 19: 644-652.
54. Campistol JM, Schena FP. Kaposi’s sarcoma in renal
39. Gu Sy, Huang TM, Ruan L, et al. First EBV vascine trial in
transplant recepients - the impact of proliferation signet
humans using recombinant vaccinia virus expressing the
inhibitor Nephrol Dial Transplant 2007; 22 (supp 1): i17-
major membrane antigen. Dev Biol Stand 1995; 84: 171-
i22.
177.
55. Guba M, von Breitenbuch P, Steinbauer M, et al.
40. Paya CV, Fung JJ, Nalesnik MA, et al. Epstein Barr virus
Rapamycin inhibits primary and metastatic tumor growth
induced post transplant lymphoproliferative disorders.
by antiangiogenesis ; involvement of vascular endothelial
ASTS / ASTP EBV-PTLD task force and the Mayo chronic
growth factor. Nat Med 2002; 8: 128-135.
organised International Consensus Development
Meeting. Transplantation 1999; 68: 1517-1525. 56. Gill PS, Tulpule A, Espina BM, et al. Paclitaxel is safe and
effective in treatment of advanced AIDS related Kaposi’s
41. Elstrom RL, Andreadis C, Aqui NA, et al. Treatment of
Sarcoma. J Clin Oncol 1999; 17: 1876-1883.
PTLD with rituximab or chemotherapy. Am J Transplant
2006; 6: 569-576. 57. Volkan P, Zinser JW, Correa Rotter R. Molecularly targeted
therapy for Kaposi’s Sarcoma in kidney transplant patient:
42. Benkerrou M, Jais JP, Leblond V, et al. Anti B-cell
case report, “ what worked and what did not” BMC Nephrol
monoclonal antibody treatment of severe post transplant B
2007; 8: 6.
lympholiferative disorder ; prognostic factors and long term
outcome. Blood 1998; 92 : 3137-3147. 58. Koon HB, Bubley GJ, Pantanowitz L, et al. Imatinib –
induced neoplasm of AIDS related Kaposi’s Sarcoma. J
43. Choquet S, Leblond V, Herbrecht R, et al. Efficacy and
Clin Oncol 2005; 23: 982-989.
safety of rituximab in B cell post transplantation
lymphoproliferative disorders. Result of prospective 59. Ramsay HM, Fryer AA, Reece S, et al. Clinical risk factors
multicenter phase 2 study Blood 2006; 107: 3053-3057. associated with nonmelanoma skin cancer in renal
transplant recipients. Am J kidney Dis 2000; 36: 167-176. cancer; Expert consensus survey. Br J Dermatol 2006;
154: 395-400.
60. Urich C, Schmook T, Sachse MM, et al. Comparative
epidemiology and pathogenic fectors for non melanoma 65. Caroll RP, Ramsay HM, Frayer AA, et al. Incidence and
skin cancer in organ transplant patients. Dermatol Surg prediction of non melanoma skin cancer post renal
2004; 30: 622-627. transplantation; a prospective study in Queensland,
Austrialia. Am J kidney Dis 2003; 41: 676-683.
61. de Fijter JW. Use of proliferation signel inhibitors in non
melanoma skin cancer following renal transplantation. 66. Herrero JI, Espana A, Quiroga J, et al. Nonmelanoma skin
Nephrol Dial Transplant 2007; 22 (supp 1): i23-i26. cancer after liver transplantation. Study of risk fectors.
Liver Transpl 2005; 11: 1100-1106.
62. Kovach BT, Sams HH, Stasko T. Systemic strategies for
chemoprevention of skin cancer in transplant recipients. 67. Campistol JM, Eris J, Oberbauer R, et al. Sirolimus therapy
Clin Transplant 2005; 19: 726-734. after early cyclosporine withdrawl reduces the risk for
cancer in adult renal transplantation. J Am Soc Nephrol
63. Berg D, Ofley CC. Skin cancer in organ transplant 2006; 17: 581-589.
recipients: epidermiology, pathogenesis and manage-
ment. J Am Acad Dermatol 2002; 47: 1-17. 68. Mathew T, Kreis H, Friend P. Two year incidence of
malignancy in sirolimus treated renal transplant recipients;
64. Otley CC, Berg D, Ulrich C, et al. Reduction of results from five multicenter studies. Clin Transplant 2004;
immunosuppression for transplant associated skin 18: 446-449.